

**Supplementary Figure 1**. **LTX-315 increases the TCR repertoire and generates novel tumor- associated T-cell clones post treatment**. **(A)** Trivariate analysis of the abundance of unique T-cell clones in blood (PBMC) baseline compared to 7 weeks after treatment was initiated. T-cell clones that were not significantly changed in frequency are depicted in *gray*, whereas those that were significantly expanding or contracting are depicted in *red* or *blue* respectively. T-cell clones colored without transparency and with a black peripheral line were also present in tumor tissue 7 weeks after treatment. T-cell clones aligned with the y-axis are novel T-cell clones after LTX-315 treatment. **(B)** The proportion of T-cell clones that significantly expanded or contracted in blood after LTX-315 treatment and that were also present in the tumor before and after treatment. Data represents the median of the samples shown in A.